← Back to Browse
ProductDiagnostic Tests

The NGAL Test

United States

CE-marked in vitro diagnostic test for early detection of acute kidney injury using the NGAL biomarker. Identifies kidney damage earlier than traditional serum creatinine and urine output methods, enabling timely clinical intervention.

Manufactured by

BioPorto Diagnostics

United States

ProNephro AKI (NGAL) is designed to aid in the risk assessment of acute kidney injury (AKI) in ICU patients 3 months to 22 years. A low NGAL value indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI and can trigger nephrology consults and interventions 2-3 days before serum creatinine rises.

View profile & products →

✦ Product-Specific Coverage

AI supplier coverage for this product

Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.

Generated for this product

AI-matched supplier coverage based on related product alternatives.

0
Relevant manufacturers
matched to this product
0
Relevant products analyzed
for supplier coverage
0
Sourcing countries
identified

Top sourcing countries

1China
57 relevant products
2United States
10 relevant products
3South Korea
7 relevant products
🔒

14 more sourcing countries available

Get free access to all sourcing countries identified for this product.

See all countries →

See the full supplier coverage for this product

Get free access to all relevant manufacturers, sourcing countries, and product alternatives.

Get Free Access →

Free for medical industry professionals.

AI-Matched Alternative Products

from other manufacturers

AI-Matched Alternative Products

from other manufacturers

3 of 105 closest product alternatives

105 products

102 more product alternatives available

Create a free account to compare more product alternatives and supplier options.

Get Free Access →

© 2026 Suplivia · Home · Browse Products